Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists hunt superbug in water and people to stop its spread

NCT ID NCT05282082

Knowledge-focused Sponsor: Erasmus Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aimed to create a smart surveillance strategy for carbapenem-resistant Pseudomonas aeruginosa (CRPA), a superbug that causes hard-to-treat infections in hospitals. Researchers collected samples from over 2,100 healthy people, patients, and hospital environments in the Netherlands, Italy, and Indonesia. By analyzing the bacteria's DNA, they hope to identify transmission routes and develop a global plan to prevent further spread.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to a globally-applicable surveillance strategy to guide actions against the spread of CRPA in hospitals and communities.
What could go wrong
This is an observational study, not a treatment trial. It provides insights but does not directly test any intervention or cure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

2,105 people

The number who actually took part.

Started

Mar 2022

Finished

Jun 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Healthy volunteers are individuals living in "high-risk areas" in one of the three cities. "High-risk areas" are areas that we expect to have a high prevalence of CRPA which may affect humans. Patients will be included within 48 hours of their admission to the hospital (non-critical medical and surgical wards) in one of the three cities. The three participating hospitals are all university hospitals.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria healthy individuals: * All healthy individuals (i.e., not hospitalized) aged 18 years or older and living in a "high-risk area" in Rotterdam, Rome or Jakarta. Exclusion Criteria healthy individuals: * No signed consent sheet. Inclusion Criteria patients: * Must be aged 18 years or older; * Should be capable of providing answers to the questions in the questionnaire by himself/herself; * Should have a minimum expected length of stay of at least 24 hours; * Inclusion only once during the sampling year. Exclusion Criteria patients: * Cystic fibrosis patients * No signed consent sheet.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Colonization, asymptomatic are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Asymptomatic Infections nosocomial infection Pseudomonas aeruginosa infectious disease Pseudomonas infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Colonization, asymptomatic Nosocomial infection Pseudomonas aeruginosa

Contacts and locations

Locations

  • Dr Cipto Mangunkusumo General Hospital

    Jakarta, Indonesia

  • Erasmus Medical Center

    Rotterdam, South Holland, 3015 GD, Netherlands

  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS

    Roma, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.